If you work in a clinical or molecular lab, you’re living this tension every day: advancements in testing keep moving forward, but reimbursement rules lag months or even years behind.
New molecular tests, infectious disease diagnostics, and proprietary laboratory developed tests (LDTs) are coming online constantly. Yet payers are still catching up on coding, coverage criteria, and what they consider “medically necessary.” That gap is where many labs see denied claims, recoupments, and unpredictable cash flow.
In our recent webinar, Lighthouse Lab Services’ Ann Lambrix, Executive Director of RCM Consulting, and Tara Cepull, Industry Status & Outreach Adviser with Quadax, broke down how MolDX, Z-codes, prior authorizations, and evolving payer reforms are reshaping reimbursement for molecular testing.
Reference Guide to Protect Your Revenue and Plan for Next Steps
MolDX vs. DEX: What’s the Difference?
One of the first points Lambrix clarified is that a lot of people mix up MolDX and DEX, and that confusion can easily lead to denials.
MolDX® is a Medicare administrative program. It was launched by Palmetto in 2011 to bring some order to the chaos of molecular and genetic test reimbursement. Over time, several other Medicare Administrative Contractors (MACs) have joined the MolDX program, while a few still operate their own local coverage determinations and policies for molecular testing.
DEX™ (the Diagnostic Exchange) is the online registry used within that framework. This is where labs register their tests, receive a unique Z-code, and go through the technical assessment (TA) process. DEX is also where you can see the CPT code MolDX expects you to bill for a given test and, once approved, how that test is priced.
The important distinction is this:
- MolDX is the policy and oversight program.
- DEX is the operational tool you interact with.
Even if your MAC isn’t part of MolDX yet, you’re probably still feeling the ripple effects. Commercial payers like UnitedHealthcare and Humana have started using the DEX/Z-code infrastructure nationwide for certain tests, regardless of which MAC region you’re in. So, this is no longer just a “Medicare thing” that only applies in certain states — it’s becoming part of the national reimbursement fabric for Molecular Testing.
Z-Codes, CPT Codes, and Technical Assessment: All Three Have to Match
One of the biggest takeaways from Lambrix’s insights was that you don’t get paid just because you got a Z-code. There are three moving parts that all have to work together: the Z-code, the CPT code, and the technical assessment.
Here’s how the process works in practice:
- You register your molecular or genetic test in DEX.
- DEX assigns your test a Z-code, which uniquely identifies that specific test at your specific lab.
- DEX also assigns a recommended CPT code for that test.
- Your test may then undergo Technical Assessment (TA) to evaluate its clinical validity and clinical utility.
From a billing standpoint, you only have a viable reimbursement pathway when all three align:
- You bill with the CPT code assigned in DEX (even if you think a different CPT would fit better).
- You include the correct Z-code on the claim in the appropriate field or loop.
- You have an approved TA for that test.
If you change any one of those pieces on your own (especially the CPT code) you’re almost guaranteed denials. As Lambrix put it, MolDX and DEX aren’t asking what you think the code should be; they’re telling you what you must bill if you want that Z-code, and test to be linked correctly in their system.
This point is especially important for labs that are used to defining their coding based on their understanding of correct coding.
Unlisted Codes and 81479: Don’t Panic
Many labs get nervous when DEX assigns an unlisted code such as 81479. Traditionally, unlisted molecular codes have been associated with uncertainty and manual review. Here’s what’s different under MolDX.
If your technical assessment is approved, MolDX may crosswalk and price that unlisted code. That means you’ll still bill the unlisted code (for example, 81479), but there will be a defined allowable associated with it. You should be able to see this in DEX under your test details.
If DEX assigns a specific CLFS code (for example, a code like 81455), then that test will be paid based on the existing Clinical Laboratory Fee Schedule.
Either way, the key idea is the same: follow what DEX gives you. If you disagree with the CPT codes recommended, you may appeal to DEX. Remember, the system is built around aligning the Z-code, CPT code, and TA; stepping outside that framework will lead to denials or underpayments.
Why Payers Are Leaning into MolDX and DEX
From the lab side, MolDX and DEX can feel like an extra layer of work. But if you look at it through the payer’s eyes, the rationale is pretty straightforward.
First, technology is way ahead of policy. Labs are innovating rapidly, especially in molecular and infectious disease testing, while CPT codes and payer policies take years to catch up. During that gap, labs often rely on unlisted codes or code stacking, and payers struggle to understand exactly what they’re paying for.
Second, Medicare is a classic “pay-and-chase” payer. In some non-MolDX regions, MACs have historically paid molecular claims for months or years, only to conduct audits later and recoup large amounts if they decide the tests weren’t covered or weren’t medically necessary. That’s stressful for both labs and payers, and it undermines financial planning.
MolDX/DEX is an attempt to shift that model to something more controlled and predictable:
- Clinical validity and clinical utility are evaluated up front through Technical Assessment.
- Z-codes give payers a consistent way to know exactly which test is being performed.
- Once a test is approved and correctly billed, payment becomes much more consistent.
Commercial payers have noticed that this approach works. As Lambrix and Cepull both emphasized, UnitedHealthcare and Humana are now requiring Z-codes and DEX registration for certain molecular tests across their Medicare Advantage, commercial, and Medicaid products. That means even if your Medicare MAC is not in MolDX, you may still be dealing with the Z-code/DEX world because your commercial payers have adopted it.
Denials: Where Labs Are Losing Money
Cepull spent a good portion of the webinar diving into denials, and it’s easy to see why. Denials are where a significant percentage of lab revenue quietly disappears.
Some of the most common issues she sees include:
- Claims missing required Z-codes, or using the wrong Z-code.
- CPT codes that don’t match the DEX assignment for the Z-code used.
- Confusion around PLA codes and CPT codes, especially when payers haven’t cleanly linked PLA codes to Z-codes.
- Payer-specific denial codes that are inconsistent and hard to interpret.
- New or emerging payers (like Optum) updating their edits and requirements quickly, often without much warning.
The financial impact is substantial. Industry data and Quadax’s experience show that:
- Roughly 10–20% of revenue may be tied up in denials at any given time.
- About 60% of denied claims are never recovered, often because labs don’t have the capacity to rework them.
- It can cost several times more to rework a denial than to submit a clean claim in the first place.
For labs already stretched thin on staffing, those numbers are concerning. But they also highlight where the opportunity lies: denial prevention and smarter lab revenue cycle management.
Building Quality into Your Revenue Cycle
One helpful mindset shift is to treat revenue cycle quality the same way you treat analytical quality. Prevention is always cheaper and more effective than rework.
Lambrix and Cepull highlighted a few core practices that every lab should have in place.
- Make audits a routine, not a reaction
Ann Lambrix, Lighthouse Lab Services
Regular revenue cycle and coding audits are essential, especially if your lab heavily depends on Molecular Testing. At minimum, you should be reviewing your patterns annually, and more often if you’re rolling out new panels or working with high-cost assays.
These audits should look at how you’re coding, how often denials occur, whether payer rules are being followed, and whether your staff understands when Z-codes and TAs are required. If you uncover issues early, you can fix them before payers do.
This is exactly where Lighthouse’s RCM consulting team can provide value: independent audits, process reviews, and practical recommendations tailored to the lab environment.
- Treat eligibility and prior authorization as strategic, not clerical
Eligibility verification and prior authorization used to be seen as routine administrative tasks. That’s no longer the case.
Labs should ensure that:
- Eligibility checks are thorough and payer-specific.
- Prior authorization requirements are clearly documented and updated as payers change their rules.
- Staff understand which tests are more likely to require prior auth or Z-code registration.
For complex molecular testing and high-cost infectious disease testing, eligibility and prior auth are strategic control points. Errors at this stage create a cascade of problems later: denied claims, delayed revenue, and manual rework.
- Standardize payer-specific coding rules
Every payer plays by its own rules, especially when it comes to molecular diagnostics. A core part of your laboratory quality management should be documenting those rules in a way that’s accessible and actionable.
That includes:
- Which tests require DEX registration and Z-codes for each payer.
- Which CPT codes must be used when a Z-code is present.
- When PLA codes are acceptable, preferred, or problematic.
- What documentation is needed to support medical necessity for each major test type.
Many labs find that a hybrid model with both an RCM consultant and lab-specific biller gives them both visibility and operational horsepower.
Prior Authorization: Burden Today, Reform Tomorrow?
Prior authorization has long been a challenge for physicians, but it’s increasingly a burden for labs as well, particularly in high-complexity molecular testing.
Tara Cepull, Quadax
Cepull shared results from a recent AMA prior authorization survey that, while physician-focused, paint a picture labs will find familiar. Almost all respondents reported care delays tied to prior authorization, many saw treatment abandoned because of PA issues, and a significant number traced serious adverse events back to PA-related delays.
On the provider side, prior authorization represents hours of manual administrative work each week. Yet many providers don’t even bother appealing denials because they assume they won’t win.
Lambrix added another important angle: in many ways, MolDX is a prior authorization surrogate for Medicare when it comes to molecular diagnostics. Instead of seeking approval for each individual order, you’re effectively getting a “global” decision on your test through the technical assessment process. If the TA is approved and you bill exactly as DEX specifies, payment becomes more predictable.
It’s also important to recognize that while there are promising efforts to reform prior authorization, both through legislation and voluntary payer pledges, those efforts are unlikely to eliminate prior auth for complex, high-dollar molecular tests. If anything, PA and MolDX-style front-end review will probably remain a fixture in these areas.
That’s why labs need to streamline their approach now, rather than waiting for a perfect policy fix that may never arrive.
Looking Ahead: Expansion of MolDX and Payment Reform
As for the future of reimbursement in this space, Lambrix talked about her “crystal ball” prediction: that more MACs (and possibly eventually all seven Medicare MACs) will join MolDX. A few years ago, that might have sounded unlikely. Today, given the demonstrated success of MolDX in controlling molecular spending and structuring coverage, it seems more like a matter of “when” than “if.”
She also pointed out that some Blue plans are exploring similar models and watching MolDX closely. That’s yet another sign that this framework is becoming the default way payers manage molecular reimbursement.
On top of that, broader payment reforms are in play. The Protecting Access to Medicare Act (PAMA) has driven years of instability for labs, with repeated reporting requirements and the potential for steep cuts to the Clinical Laboratory Fee Schedule. New legislative proposals like the RESULTS Act aim to bring more stability by using more comprehensive commercial data, capping reductions, and reducing the reporting burden.
The legislative path remains uncertain, but one trend is clear: payers and policymakers alike are seeking more data-driven, structured ways to pay for lab testing; especially high-cost molecular diagnostics.
What Your Lab Can Do Right Now
With all of this in mind, what are some practical steps you can take in the next 30–90 days?
Here’s a simple roadmap:
- Review your payer mix. Identify how much exposure you have to UnitedHealthcare, Humana, Medicare Advantage plans, and Medicaid products that are already using Z-codes and TA requirements.
- Inventory your molecular test menu. Determine which tests are registered in DEX, which still need Z-codes, and whether any high-volume tests are at risk due to failed or pending TAs.
- Compare your coding to DEX. Make sure the CPT codes you’re billing actually match the codes DEX shows for your Z-codes. Correct any discrepancies now.
- Schedule an RCM audit. Whether you use Lighthouse, or your internal team, commit to regular audits focused specifically on molecular reimbursement.
- Train your team. Ensure your billing and front-end staff understand Z-codes, TAs, payer-specific rules, and when prior authorization is required.
- Bring RCM into test development. When planning new molecular or infectious disease panels, involve RCM experts early. Don’t wait until the test is live to think about reimbursement.
These steps won’t eliminate every denial or every policy headache, but they will put your lab on much firmer footing as reimbursement continues to evolve.
Next Steps for Your Lab
At Lighthouse Lab Services, we help labs start, run, and grow, and that includes making sure their lab revenue cycle management supports long-term success. Our RCM Consulting team, led by Lambrix, works with labs across the country to strengthen processes, perform audits, and align test menus with payer reality.
Our partners at Quadax specialize in laboratory billing execution, from pre-billing through appeals, so labs can focus on quality and operations without losing sight of reimbursement.
If your lab is expanding molecular testing, struggling with denials, or unsure how MolDX and Z-codes will affect your future, we’d be happy to talk.
Contact us today for a complimentary consultation and billing analysis.
